Among these molecular subtypes, HER2+ patients make up about 15%–20% of all breast cancer cases and shows high malignancy, high rate of recurrence and metastasis, and poor prognosis (Guarneri et al., 2013). The gene discussed is ERBB2; the disease is breast carcinoma.